Denali Advisors LLC Has $289,000 Position in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Denali Advisors LLC raised its position in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 5.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,700 shares of the company’s stock after acquiring an additional 200 shares during the quarter. Denali Advisors LLC’s holdings in GE HealthCare Technologies were worth $289,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in GEHC. LGT Financial Advisors LLC lifted its stake in shares of GE HealthCare Technologies by 1,673.3% during the 3rd quarter. LGT Financial Advisors LLC now owns 266 shares of the company’s stock worth $25,000 after buying an additional 251 shares during the last quarter. Capital Performance Advisors LLP acquired a new stake in shares of GE HealthCare Technologies during the 3rd quarter worth about $26,000. Ashton Thomas Securities LLC acquired a new stake in shares of GE HealthCare Technologies during the 3rd quarter worth about $26,000. Darwin Wealth Management LLC acquired a new stake in shares of GE HealthCare Technologies during the 3rd quarter worth about $31,000. Finally, Continuum Advisory LLC lifted its stake in shares of GE HealthCare Technologies by 101.8% during the 3rd quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock worth $31,000 after buying an additional 168 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Jefferies Financial Group upgraded shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and raised their target price for the stock from $95.00 to $103.00 in a research note on Wednesday, January 8th. Citigroup raised their price target on shares of GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Finally, Wells Fargo & Company raised their price target on shares of GE HealthCare Technologies from $96.00 to $103.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, GE HealthCare Technologies has an average rating of “Moderate Buy” and an average target price of $97.67.

GE HealthCare Technologies Trading Down 1.4 %

Shares of GE HealthCare Technologies stock opened at $89.40 on Friday. The firm’s 50 day moving average is $86.00 and its 200 day moving average is $86.07. The company has a current ratio of 1.04, a quick ratio of 0.83 and a debt-to-equity ratio of 0.88. GE HealthCare Technologies Inc. has a 1 year low of $74.51 and a 1 year high of $94.80. The firm has a market capitalization of $40.88 billion, a PE ratio of 20.65, a price-to-earnings-growth ratio of 3.19 and a beta of 1.15.

GE HealthCare Technologies (NASDAQ:GEHC) last posted its earnings results on Thursday, February 13th. The company reported $1.45 EPS for the quarter, topping the consensus estimate of $1.26 by $0.19. GE HealthCare Technologies had a net margin of 10.13% and a return on equity of 25.74%. The business had revenue of $5.32 billion for the quarter, compared to the consensus estimate of $5.33 billion. Equities research analysts forecast that GE HealthCare Technologies Inc. will post 4.68 earnings per share for the current fiscal year.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.